eCential Robotics and ChoiceSpine Announce Long-Term Partnership to Enhance Robotic Spine Implant Surgery

eCential Robotics, a French growth company that designs, manufactures, and markets the first unified 2D/3D robotic imaging and surgical navigation system for bone surgery indications and ChoiceSpine LLC, a US privately-held spinal implant company, announced today their long-term partnership to offer a common optimized solution. This system combines navigation, robotics, and implant systems that are easy to use, accurate for spine surgeons, and benefits the patient.

Combining innovative technologies and strengths

After starting the process in 2021, eCential Robotics and ChoiceSpine agreed to partner their technologies with spine robotic surgeries. Built on the technical excellence of the products and a common long-term vision, a collaboration combining two critical assets is emerging:

eCential Robotics’ Platform

The eCential Robotics platform pulls together intraoperative 2D/3D imaging, navigation, and robotics in its core design as the only available fully-unified, single-device solution with a single-user interface. In addition, the eCential Robotics platform is an open solution, catering to different surgeons’ preferences. Built around a range of applications (“Apps”) currently dedicated to spine surgery, there are plans for multiple bone surgery indications soon.

ChoiceSpine LLC Offerings

ChoiceSpine is a spinal implant company with a robust, comprehensive hardware and orthobiologics portfolio. The Knoxville-based company is recognized for introducing innovative and niche solutions to the spinal implant market, emphasizing MIS solutions, such as the Thunderbolt™ Minimally Invasive Pedicle Screw System and the Triton™ 3D printed SI Joint Fixation System. Other differentiating technologies offered by ChoiceSpine include proprietary BioBond™ 3D printed interbodies, a shallow docking access system for direct lateral surgery, and multiple cervical fusion options. In addition, the orthobiologics portfolio offers bone graft solutions, including 100% demineralized bone matrix, cortical fibers, synthetics, a cellular bone matrix, structural allograft, and allograft sponge options.

Taking full advantage of ChoiceSpine implant solutions using eCential Robotics’ unified platform

Navigation and robotics will make it possible to fully utilize the specific features of ChoiceSpine’s portfolio and offer optimization of the surgical procedure. It also brings spine surgeons and patients the benefits of the latest advances in navigation, robotics, and implant technologies.

“By enabling eCential Robotics’ platform to navigate ChoiceSpine implants with our robotic arm, we will optimize and add value to our unified and universal solution for the benefit of surgeons and patients,” said Mrs. Laurence Chabanas, eCential Robotics Chief Strategy Officer. “This partnership is a part of eCential Robotics’ open model strategy. Since our ambition is to offer a unique platform for bone surgery in the operating room and become a standard, we are open to collaborating with implant companies to combine our technologies and offer optimized navigation and robotics for the implementation proposed to the patient,” she added.

Steve Ainsworth, PhD, ChoiceSpine’s EVP of Strategy and Technology, said: “This combination of our innovative cultures will allow us to expand our clinical value by fully encompassing the surgical experience. We believe the eCential Robotics platform, in conjunction with our comprehensive spinal implant and orthobiologics portfolios, will lead the way in advancing spine surgery. This partnership is just one example of how ChoiceSpine brings technically superior spinal devices to the market and is doing spine the right way.”

Initiate eCential Robotics penetration of the US market

After receiving FDA 510(k) clearance of its unified platform’s 2D/3D robotic imaging technology in 2021, eCential Robotics has conducted pre-clinical evaluation tests in the USA, in Q1 2022, with neurosurgeons and orthopedic surgeons. In addition, it has launched the process to obtain clearance for its navigation and collaborative robot (CoBot) device. To support the penetration of the North American market, an eCential Robotics, Inc. subsidiary was created in December 2020.

“This close cooperation with a US company provides eCential Robotics with access to complementary technologies and allows us to initiate and expand our footprint in the US market,” declared Mrs. Laurence Chabanas, eCential Robotics Chief Strategy Officer.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”